



**The United Laboratories International Holdings Limited  
Donates Medicines and Makes Donation Totaling RMB 5 Million  
to the Quake-hit areas in Sichuan**

(13 May 2008 – Hong Kong) – The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC, donated antibiotics finished products worth RMB 4.2 million and made a donation of RMB 800,000 to quake-hit areas in Wenchuan, Sichuan Province in China as an immediate disaster relief.

Adhering to the enterprise’s objective of “Love China, For China”, Mr. Choy Kam Lok, Chairman of TUL, organized and launched initiatives to call for fundraising and donations for goods and materials among its staff members throughout China immediately after he was aware of the quake. He also actively made contact with Pengzhou City People’s Government in the location at which TUL’s Chengdu production base is situated to take part in disaster relief. In addition, led by Mr. Choy, the Company donated quality antibiotics finished products worth RMB 4.2 million in terms of value (330 cartons of antibiotics finished products weighting 8 tons in total) to the Red Cross at Pengzhou City.

In addition, TUL’s staff members in Hong Kong, Zhuhai, Zhongshan, Kaiping, Chengdu and Inner Mongolia and different offices in China contributed to the fund for the quake-hit areas enthusiastically and generously, raising a donation amounting to RMB 800,000 in total. TUL would like to express the deepest condolences for the victims in the quake-hit areas, hoping them to overcome the difficulties as soon as possible.

- End -

**Company Background**

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the major manufacturers of antibiotic products in China and principally engaged in the manufacturing and selling of bulk medicine and intermediate products used to produce antibiotics, and also antibiotics as finished goods. The Group also produces and sells, in smaller amounts, cough syrup, anti-allergy medicine as well as empty capsule casings. As of 31 December 2007, the Group has a total of 150 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 31 bulk medicines and 119 finished products.

For further enquiries, please contact  
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau  
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952  
Fax: (852) 3170 6606  
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/  
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com